This company is no longer active
Magenta Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Magenta Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 24.0% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10
Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate
Aug 25Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow
Jun 18We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate
May 09Magenta Therapeutics EPS beats by $0.04
May 06What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Mar 17Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Jan 23
Magenta Therapeutics announces expected 2021 highlights milestones
Jan 11What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Dec 01In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Magenta Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2023 | N/A | -69 | -70 | -73 | N/A |
| 3/31/2023 | N/A | -83 | -83 | -83 | N/A |
| 12/31/2022 | N/A | -76 | -67 | -67 | N/A |
| 9/30/2022 | N/A | -76 | -66 | -66 | N/A |
| 6/30/2022 | N/A | -77 | -68 | -66 | N/A |
| 3/31/2022 | N/A | -77 | -64 | -62 | N/A |
| 12/31/2021 | N/A | -71 | -61 | -60 | N/A |
| 9/30/2021 | N/A | -70 | -59 | -58 | N/A |
| 6/30/2021 | N/A | -70 | -58 | -58 | N/A |
| 3/31/2021 | N/A | -72 | -64 | -64 | N/A |
| 12/31/2020 | N/A | -75 | -64 | -64 | N/A |
| 9/30/2020 | N/A | -80 | -66 | -66 | N/A |
| 6/30/2020 | N/A | -83 | -64 | -63 | N/A |
| 3/31/2020 | N/A | -82 | -61 | -59 | N/A |
| 12/31/2019 | N/A | -77 | -60 | -57 | N/A |
| 9/30/2019 | N/A | -70 | -61 | -54 | N/A |
| 6/30/2019 | N/A | -65 | -62 | -53 | N/A |
| 3/31/2019 | N/A | -61 | -56 | -47 | N/A |
| 12/31/2018 | N/A | -58 | -50 | -42 | N/A |
| 9/30/2018 | N/A | -49 | -41 | -37 | N/A |
| 6/30/2018 | N/A | -40 | -34 | -32 | N/A |
| 3/31/2018 | N/A | -42 | -30 | -28 | N/A |
| 12/31/2017 | N/A | -36 | -24 | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MGTA's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if MGTA's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if MGTA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if MGTA's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if MGTA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MGTA's Return on Equity is forecast to be high in 3 years time